Please login to the form below

Not currently logged in
Email:
Password:

UK healthcare research gets £208m boost

Consortium including Roche Diagnostics and GE Healthcare among programmes to secure government funding

Three healthcare research programmes will receive a total investment of £208m as part of the UK Research Partnership Investment Fund (UK RPIF) for long-term university projects.

Health-related projects successful in this first round of bids for the fund included a £138m partnership between the University of Oxford and a consortium comprising Synergy Health, Cancer Research UK, Roche Diagnostics, GE Healthcare and the Oxford University Hospitals NHS Trust.

This project aims to establish a new centre for targeted cancer research, and will develop, test and implement personalised minimally invasive treatments, combined with targeted diagnosis, imaging and therapy.

The University of Oxford will receive a further £32m to support its partnership with another consortium that includes UCB Pharma, Ludwig Institute for Cancer Research, Janssen Pharmaceutica NV, Boehringer Ingelheim and Takeda and will set up a new centre for drug target discovery and for research based on medical data sets.

Finally, £38m will be available to the University of Dundee to build a new translational research centre, which will aim to increase the speed of development for viable treatments in cancer, infectious diseases, eczema and diabetes. This project has co-investment from the Wellcome Trust and others.

The fund was launched in April 2012, with an initial government investment of £100m, although this was “heavily oversubscribed and received an overwhelming number of high quality bids”, according to the Department for Business, Innovation and Skills (BIS).

Universities were able to bid for between £10m and £35m per project, although, in order to obtain this money, these institutes had to match the funding by at least double from private companies or charities – something achieved by both Dundee and Oxford.

An extra £200m worth of funding has now been added by the government on top of the already announced £100m, widening coverage from the fund, which also covers industries such as engineering and mobile communications.

According to BIS, the overall investment from industry, university and government is expected to top £1bn and the fund has now reopened for further bids.

9th October 2012

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...